Androgen deprivation and radiotherapy with or without docetaxel for localized high-risk prostate cancer: Long-term follow-up from the randomized NRG Oncology RTOG 0521 trial

Authors

Oliver Sartor, Tulane University
Jeff M Michalski, Washington University School of Medicine in St. Louis
et al.

Journal

European Urology

Publication Date

8-1-2023

Volume

84

Issue

2

First Page

156

Last Page

163

Document Type

Open Access Publication

DOI

10.1016/j.eururo.2023.04.024

Rights and Permissions

Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023 Aug;84(2):156-163. doi: 10.1016/j.eururo.2023.04.024. Copyright 2023 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Sartor, Oliver; Michalski, Jeff M; and et al., "Androgen deprivation and radiotherapy with or without docetaxel for localized high-risk prostate cancer: Long-term follow-up from the randomized NRG Oncology RTOG 0521 trial." European Urology. 84, 2. 156 - 163. (2023).
https://digitalcommons.wustl.edu/oa_4/2514

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.